Drug
Single dose placebo
Single dose placebo is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
4
80%
Ph phase_3
1
20%
Phase Distribution
4
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Terminated(1)
Detailed Status
Completed4
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 14 (80.0%)
Phase 31 (20.0%)
Trials by Status
completed480%
withdrawn120%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_1
A First in Human Trial Evaluating THB335 in Healthy Participants
NCT06425861
completedphase_1
A First-In-Human Study of Single and Multiple Ascending Doses of Oral SUL-238 in Healthy Subjects
NCT06277492
completedphase_1
Putative Cognitive Enhancer VU319
NCT03220295
completedphase_1
Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy
NCT02494024
withdrawnphase_3
Therapeutic Effect of Sildenafil in Patients With Coronary Vasospasm
NCT00454714
Clinical Trials (5)
Showing 5 of 5 trials
NCT06425861Phase 1
A First in Human Trial Evaluating THB335 in Healthy Participants
NCT06277492Phase 1
A First-In-Human Study of Single and Multiple Ascending Doses of Oral SUL-238 in Healthy Subjects
NCT03220295Phase 1
Putative Cognitive Enhancer VU319
NCT02494024Phase 1
Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy
NCT00454714Phase 3
Therapeutic Effect of Sildenafil in Patients With Coronary Vasospasm
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5